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There is increasing concern about the reliability of biomedical research, with recent 
articles suggesting that up to 85% of research funding is wasted. This article argues 
that an important reason for this is the inappropriate use of molecular techniques, 
particularly in the field of RNA biomarkers, coupled with a tendency to exaggerate 
the importance of research findings.  
Time to listen! 
Most researchers are aware that the translation into clinical practice of even the most 
promising findings of basic research is slow and rare [1] and that the clinical 
effectiveness of drugs cannot be predicted reliably from early research-based 
evidence [2]. A string of five articles and an editorial printed in the Lancet in early 
2014 addressed this issue, reaching the staggering conclusion that 85% of biomedical 
funding is wasted on research that is ill conceived, poorly executed, inappropriately 
analysed, inadequately reported, side-tracked by bias and stifled by red tape.  
The first article considers research priorities and questions their relevance for human 
health in the context of a worldwide investment in biomedical research of around 
US$240 billion [3]. The second highlights the usual absence of detailed written 
protocols for and poor documentation of research and comments on the systematic 
preference for quantity rather than quality, and novelty rather than reliability [4]. The 
third article discusses the modern approach to the regulation, governance, and 
management of biomedical research and emphasises how inefficient management can 
easily compromise the interests of patients and public [5]. The fourth points out that a 
large percentage of health research-associated protocols, full study reports and 
participant-level datasets are rarely available, that there is selective reporting of 
methods and results and that this leads to the introduction of bias, detrimentally 
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effects the care of patients and wastes huge amounts of research funding [6]. The final 
article re-emphasises the absolute requirement for accurate, exhaustive and 
transparent reporting and notes that whilst reporting guidelines are important, they are 
all much less adopted and adhered to than they should be [7]. Finally, the editorial 
discusses the consistent and colossal failure of initially promising research findings to 
translate into improvements in health in light of the many, economic, political, social 
and cultural factors that influence researchers, funders, regulators, institutions and 
companies [8]. The authors make the revolutionary suggestion that rather than using 
journal impact factors to assess academics, it might be more constructive to gauge the 
methodological rigour, transparency of reporting and reproducibility of results of their 
output, which would of course facilitate the publication of more reliable and 
biologically relevant data. 
Time to act! 
Clarion calls don’t come much louder, insistent or with more authority. The authors’ 
principal recommendations involve proposals to improve every aspect of research 
project procedures relating to standardisation, governance and the research 
environment infrastructure:  
• Enhance translational research outcomes by increasing clarity from 
researchers, funders and regulators with regards to research proposal 
justification and transparency of protocols [3]. 
• Make research results more reliable and relevant by ensuring public 
availability of protocols, analysis plans, raw data and providing continuous 
training and professional development coupled to reward incentives [4].  
• Streamline management of biomedical research to make it fit for purpose by 
harmonising regulations and processes affecting research, together with 
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appropriate research designs and monitoring [5].  
• Make information more widely available by adopting performance metrics for 
distribution of research protocols and results, development of standards for 
data sharing practices and introducing legally-enforced policies on 
information sharing [6].  
• Ensure that research reports address the needs of research users by 
encouraging better and more complete reporting and investing in the 
development and maintenance of an infrastructure for reporting, reviewing 
and archiving [7]. 
Is anyone listening? 
These are of course very laudable aims and all make perfect sense, yet it is hard not to 
cast a weary eye over previous such propositions, generally published by the same 
cohort of authors in similarly prominent high impact factor journals. It really is 
striking just for how long there have been reports about the poor quality of research 
methodology, inadequate implementation of research methods and use of 
inappropriate analysis procedures as well as lack of transparency of reporting. All 
have failed to stir researchers, funders, regulators, institutions or companies into 
action.  
For example, an earlier, shorter, but similar narrative of the problems facing applied 
research expressed surprise at the level of waste caused by issues such as poorly 
designed research studies pursuing the wrong questions, then either delaying or 
failing to publish in peer-reviewed journals and finally reporting outcomes selectively 
[9]. The authors’ list of recommendations to address these issues was rather similar to 
the ones published five years later, and is echoed by several complementary analyses 
of the challenges facing  –omics research with regards to sample size and bias [10], 
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validation practices [11] and design, conduct, and analysis of such studies [12]. 
Whether these expositions have had much impact is anyone’s guess, but the fact that 
there is an unremitting reiteration of the same issues suggests not. Remarkably in this 
age of supposed austerity, neither politicians nor the public seem to care that the 
majority of research effort is wasted. It is shocking that whilst primary health care 
budgets are being trimmed, patient waiting times are increasing and the medical 
infrastructure is crumbling, no media investigation scrutinises the huge waste that is 
so evident to researchers themselves and, if stopped, would bring huge benefits to 
“our health, our comfort and our grasp of truth” [12]. It is truly extraordinary that 
whilst most researchers are aware of the fundamental flaws afflicting biomedical 
research, very few individuals, institutions, journal editors or funding agencies are 
prepared to put their heads above the parapet of what sometimes looks suspiciously 
like conspiratorial silence. 
Lack of reproducibility 
There has been a view for some time that the major problem no longer is the validity 
of expression measurements, but rather, the reliability of inferences from the data 
[13]. This conveniently disregards the fact that the results from thousands of these 
studies remain in the scientific literature and are likely to confuse current opinions 
and confound future studies. Furthermore, whilst inappropriate data analysis is of 
course a major problem, the widespread disregard for and dismissal of technical 
variability continues to be at the heart of much of the reproducibility endemic in 
biomedical research. This is most obviously demonstrated by the fact that 
independent researchers cannot reproduce the vast majority of peer-reviewed 
published work. 
Whilst repeatability, the successful replication of results and conclusions from one 
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study in the same laboratory, is important, reproducibility, defined as the independent 
confirmation of results and conclusions from a study, is the bedrock on which the 
scientific principle is based. Sadly, it has become clear that the results reported by 
most publications in the biomedical field do not fulfil that basic criterion. In a recent 
investigation at least half of researchers surveyed had the personal experience of 
being unable to reproduce published data and many were unable to resolve the issue 
even when helped by original authors [14]. In another investigation 11/12 (92%) 
studies could not be reproduced when the methods outlined in the original papers 
were replicated exactly, 26/38 (68%) when the methods were adapted and 2/2 (100%) 
when different methods were used [15]. Incidentally, it is unclear whether the authors 
analysed 67 or 57 projects, as the numbers from one of their figures add up to 67, 
whereas those from another add up to 57. A third study could not reproduce 47/53 
(89%) of findings even when the laboratories that conducted the original experiments 
were consulted about their methods and, in some cases, experiment were repeated in 
the original laboratory [16]. Tellingly, all studies for which findings could be 
reproduced provided complete information on reagents and authors had paid close 
attention to controls and investigator bias. An examination of 271 in vivo studies 
using rodent models or non-human primates concluded that only 60% of the articles 
included information about the number and characteristics of the animals and only 
70% provided detailed descriptions of the statistical analyses [17]. In a similar vein, 
54% of all resources referred to in over 200 recent publications in the fields of 
Neuroscience, Developmental Biology, Immunology, Cell and Molecular Biology and 
General Biology could not be adequately identified, regardless of domain, journal 
impact factor, or reporting requirements [18]. Yet another investigation set out to 
assess the study design, statistical analyses, and reporting of 156 papers published in 
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2008 on cerebrovascular research. Few papers were hypothesis-driven or properly 
designed, many did not include adequate information on methods and results and 
were characterised by poor statistical details [19]. All these events lead to the 
inevitable conclusion that there is a spectacular lack of attention to detail by 
researchers, reviewers and editors.  
Technical issues 
The viewpoint that there is no longer a problem with the validity of expression 
measurements is also challenged by the clear evidence that molecular techniques can 
be unfit for purpose. The problems associated with real-time quantitative PCR 
(qPCR) have been extensively aired [20-28], but the emphasis on qPCR has concealed 
the complications associated with the reverse transcription (RT) step, which converts 
RNA into cDNA. RT is a basic and essential molecular technique that feeds into a 
number of other methods that have become the mainstay of applications in modern 
biology, diagnostics, medicine, forensics and biotechnology. This reaction is carried 
out by a choice of different enzymes with different properties that are not just 
enzyme-specific but are also dependent on the advanced buffers supplied with the 
enzymes. There was early recognition that a consideration of mRNA structure is 
essential prior to any investigation into gene expression [29] and that reverse 
transcriptases (RTases) differ in their ability to transcribe through the extensive 
secondary structure in mRNA [30, 31]. This led to the realisation that both technical 
and biological variability had to be considered when analysing results from RT-qPCR 
experiments and that the variability of the RT step presented an important impediment 
to reliable data interpretation [32]. Subsequent reports showed that the method of 
cDNA priming affects both accuracy and reproducibility of RT-qPCR experiments 
[33, 34] and that reactions primed by target-specific primers are linear over a wider 
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range than similar reactions primed by random primers [35]. The first empirical 
evidence for high variability being an inherent property of the RT step was provided 
in 2004 with two rather important, but woefully overlooked publications. The first 
showed that RT-qPCR gene expression measurements are comparable only when the 
same priming strategy, reaction conditions and RNA concentration are used in all 
experiments [36]. The second reported RT- and target-dependent cDNA yields that 
differed by up to 100-fold [37], something that also applies to digital RT-PCR [38]. 
The paper’s judicious recommendation that assays should be run at least as duplicates 
starting with the reverse transcription reaction continues to be ignored, even though 
the soundness of that advice was demonstrated by a follow-up publication [39]. Yet 
another paper reported gene-related factors as the primary determinants of RT 
variability and called for an evaluation of the RT robustness of control genes in RT-
qPCR normalisation [40]. A recent paper has demonstrated that the fold changes 
reported by most RNA biomarkers are well within the range of variability observed 
when multiple RT reactions are carried out on the same template [41]. The 
conclusions from these papers are rather stark and place question marks behind many 
of the results reported not just in the biomedical literature but in the scientific 
literature as a whole. Unfortunately, recommendations for improvement are 
universally ignored and a large number of publications that use the RT step are 
characterised by inadequate and non-transparent reporting and conclusions that are 
based on expression changes well within experimental variability. 
MIQE 
The “minimum information for publication of qPCR experiments” (MIQE) guidelines 
constitute a list of recommendations that target the reliability of qPCR results, with 
the aim of helping to ensure the integrity of the scientific literature, promote 
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consistency between laboratories, and increase experimental transparency [25]. They 
are the most widely cited of such initiatives, which include MIAME [42] and 
MISFISHIE [43] targeted at various molecular techniques. MIQE is based on an 
earlier proposal aimed at improving the quality of RT-qPCR experiments in 2002 [44] 
and covers every aspect important to the qPCR assay itself, as well as issues relating 
to pre- and post-assay parameters. By 2009 it was pretty obvious that many 
publications using PCR-based methods were seriously flawed and that this impaired 
the readers’ ability to evaluate critically the quality of the published results. The 
actual trigger for the publication of the MIQE guidelines was provided by the after 
effects of a paper that used RT-qPCR to detect measles virus in children with autism 
[45]. These results were never reproduced independently [46-48] nor repeated by the 
authors themselves [49]. However, an analysis of the raw data underlying the original 
publication revealed a series of mistakes, inappropriate analysis methods and 
misinterpretations that completely invalidated any of the paper’s findings [50, 51]. 
Despite the presentation of detailed evidence at the major autism trials in 2007 in the 
USA, three initial judgements and three subsequent appeals judgements confirming 
that the underlying data were unreliable, this paper has never been retracted and its 
false conclusions remains unrestricted in the scientific literature. 
The number of citations of the original MIQE publication in the peer-reviewed 
literature is just passed 3,000 and it has been followed by several editorials on their 
implementation [26, 52, 53] and has encouraged the publication of the MIQE 
guidelines for digital PCR [54]. All major instrument and reagent manufacturers 
incorporate the guidelines into training their field application specialists, actively 
encourage their implementation, support and organise world-wide workshops and 
publish effective guides to help their implement [55, 56]. Unfortunately, researchers 
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themselves are far less enthusiastic and in addition to the thousands of peer-reviewed 
papers that are already published, thousands more are published every year without 
regard for the MIQE guidelines and report results and conclusions that are unlikely to 
be correct [57, 58]. A recent survey of qPCR-based publications found that the 
problems addressed by the MIQE guidelines continue to persist [28, 59] and an 
investigation focusing on normalisation procedures in RT-qPCR-associated colorectal 
cancer biomarkers concluded that virtually none of the studies could be reliably 
assessed [60]. 
Biomarkers 
The identification of clinically useful biomarkers has been one of the most active 
areas of research, with tens of thousands of papers claiming to have identified a wide 
range of diagnostic, prognostic or predictive biomarkers of human disease [8]. 
However, conclusions are often based on large-scale measurements of biological 
processes that “drown” any understanding in a “sea of measurements” [61] and 
inapplicable statistics [62]. This headlong stampede has only occasionally been 
punctuated by thoughtful, insightful and hence ignored counsels for cautions such as 
that provided by one of the earliest discussions of biomarkers that also included a 
checklist for evaluating their reliability prior to use in a clinical context [63].  
The starting point for most biomarkers continues to be the analysis of microarray 
results, even though there is plenty of evidence that should council caution. One study 
that deserves to be considered more widely, highlights the discordance between 
microarray results and those from non-microarray-based clinical and biological data 
[64]. Others have identified poor study design and patient selection, reliance on p-
value as well as technical and analytical issues as obstacles in the identification of 
practically useful biomarkers, with suitable marker reporting recommendations 
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thrown in for good measure [65, 66]. A fairly recent report comments that “the most 
spectacular published signatures predictive for chemotherapy response are based on 
unreliable data” [67]. Another analysis is more optimistic in that it suggests that 
“reproducible [microarray] data can be achieved and clinical standards are beginning 
to emerge”, but adds the caveat that there is a need for establishing a suitable 
workflow to “correctly sample a tumour, isolate RNA and process this for microarray 
analysis, evaluate the data, and communicate findings in a consistent and timely 
fashion” [68].  
The need for easy and complete public data access [7] and data checklists [69] is 
highlighted by the results of studies that reanalyse such data and cannot reproduce the 
original analyses. An analysis of 46 microarray studies addressing major cancer 
outcomes revealed that they were characterised by selective data analysis and 
discussion of results [70], whereas the analyses from only two of 18 microarray-based 
gene expression profiling studies could be reproduced [71]. Suboptimal design and 
inadequate assay information are typical features of cancer prognostic marker studies 
[72] and when combined with the strong reporting bias characteristic of many articles 
suggests that this literature may be largely unreliable [73]. The problem is as serious 
today as it was five, ten and 15 years ago. A recent microarray study found that the 
human genomic response to acute inflammatory stresses is not reproduced in current 
mouse models [74], a finding that challenges the use of mice as essential animal 
models in biomedical research. A reanalysis of the data not only found that human 
and murine gene expression patterns associated with inflammatory conditions are 
congruent, but identified a number of pathways commonly regulated in humans and 
mice [75]. Incidentally, analysis-related discordance is just as apparent in other 
biomedical areas of research: 35% of published reanalyses of data from randomised 
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clinical trials (RCTs) led to changes in findings that implied conclusions different 
from those of the original article about the types and number of patients who should 
be treated [76]. In addition, not only are many publications describing RCT outcomes 
inconsistent with their protocol, but there is clear evidence for publication as well as 
outcome reporting bias. Studies reporting significant results are more likely to be 
published and outcomes that are statistically significant have higher odds of being 
fully reported [77]. If outcomes of RCTs are to be clinically useful, there is an 
obvious need to publish all results and outcomes, regardless of their significance. 
Next generation sequencing (NGS), which allows hypothesis-neutral analysis with 
accuracy and a wide dynamic range and has started to supersede microarrays, is not 
exempt from these challenges. The variable lengths of RNA obtained after 
fragmentation prior to sequencing can be a source of bias, resulting in incorrect 
ranking of differentially expressed genes [78] and the technical variability of 
transcriptome sequencing experiments is sufficiently high so that RNA abundance 
estimates can substantially disagree even when coverage levels are high [79]. Quality 
assessment of sequencing data also appears to be somewhat less than complete, as 
witnessed by the surprise expressed by one group of authors when they noticed that 
standard DNA alignment algorithms assume that sequences are accurate and do not 
allow for the systematic incorporation of quality parameters into sequence alignments 
[80]. Unless prompt action is taken, it is easy to see how NGS data will become as 
unreliable as those obtained from qPCR and microarray experiments, except that there 
will be vastly more of it and troubleshooting will be proportionately more difficult. 
Hype and Retractions 
The peer-reviewed literature is widely perceived as comprising articles that have been 
carefully evaluated by experts in the field for methodological consistency, 
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completeness and soundness as well as for the logical consistency of scientific claims 
based on experimental results. Whilst it is acknowledged that not every conclusion is 
correct and that subsequent new data can lead to a re-evaluation of those findings, the 
combination of rigorous peer-review and publication in reputable journals bestows on 
peer-reviewed papers the appearance of abidance, authenticity and authority.  
Whatever the veracity of this perception, the route by which research findings are 
disseminated to a wider public is considerably less assured. An examination of press 
releases by high-profile medical journals found that these do not routinely highlight 
study limitations, disclose the role of industry funding and present findings perceived 
to be newsworthy in a way that may exaggerate their importance [81]. The somewhat 
unhelpful advice of Nature Genetics for a scientist who finds his work being thus 
glorified is to reduce the hype by explaining the implications of the work clearly 
“without using our field’s rich jargon” [82]. Unselective press coverage is also ill 
advised, as demonstrated by a study that followed up the work presented in 147 
conference abstracts and reported in 252 news stories [83]. After three years 25% of 
abstracts remained unpublished, 25% were published in low impact factor journals 
and 50% in journals with high impact factors. Thirty nine publications chosen for 
front-page coverage followed the same pattern, suggesting that media attention is 
undiscerning and not focused on quality research. Most of these reports would have 
been preliminary findings with tentative validity and indiscriminate press coverage is 
likely to create a misplaced impression of confidence and validity and is detrimental 
to engendering trust in research or individuals engaged in research.  Interestingly, 
sometimes even researchers themselves cannot agree on the relevance of their own 
published work. It should not be unreasonable to expect that all authors contributing 
to a research publication agree on the interpretation of results and any conclusions 
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that are put forward. Remarkably, that is not necessarily the case as revealed by the 
results of a small study of ten papers that appeared in The Lancet [84].  These 
indicated that the discussions did not reflect the opinions of all contributing authors 
and that the authors frequently disagreed about the importance and implications of 
their own findings and where their research was heading.  
Sometimes, it is necessary for a published article to be retracted. For example, a high 
profile article that used publicly available data to identify signatures from microarray 
profiles of human cancer cell lines with known in vitro drug sensitivity or resistance 
to predict in vivo chemotherapeutic responses [85] had to be withdrawn [86] after 
clinical trials had started because independent reanalysis of the data showed 
unintentional mislabelling and indexing errors that resulted in none of the original 
results being reproducible [87]. Retractions make up a miniscule percentage of all 
publications (871/>17 million between 1950 and 2007) [88], although the number of 
articles retracted per year has increased by between 11- and 19 fold from 2001 to 
2010 [89]. Editors of high impact factor journals often use another device, 
“expressions of concern”, prior to retraction to question published data, with six 
journals accounting for 40% of such notifications [89]. Ironically, there is 
disagreement in the literature about the effects and subsequent impacts of retracted 
publications.  It is not clear whether there is a correlation between journal impact 
factor and number of retractions, with one analysis showing none [90] and another 
reporting a strong correlation [91]. Certainly our own data show very clearly that 
there is a negative correlation between transparency of reporting and journal impact 
factor [28].  
The most common reason for retraction is the uncovering of a scientific mistake, 
although there is increasing evidence of fabrication and data plagiarism [92-94]. 
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Neither cause is usually cited as a reason for retraction [95], even though these papers 
represent a calculated effort to deceive [96]. Hence it is rather disconcerting that 
retractions may not be an effective means of removing fraudulent results from the 
literature [97]. An analysis of the impact of retracted articles in the biomedical 
literature from 1966 to 1997 found that even after publication of the retraction most of 
these articles continue to be cited as valid work with no mention of the retraction [92], 
with most citations implicitly or explicitly positive [98] even up to 24 years post 
retraction [99]. A more recent publication also found that a retraction did not affect 
the paper’s citations rate within 12 months of retraction [100] and an investigation of 
the effect of rebuttals on seven high-profile original articles found that original 
articles were cited much more frequently than the rebuttals, with no reduced effect on 
annual citation numbers [101]. In contrast, other reports found that retraction 
significantly reduced subsequent citation [102, 103] and that this reduction extends to 
the authors’ other published work [104]. Remarkably, an unexpected 18 % of authors 
self-cite retracted work post retraction [why would they do that?], but only 10 % of 
those authors also cite the retraction notice [105]. Around 1% of the NIH budget 
between 1992 and 2012 (US$58 million) was spent on papers retracted due to 
misconduct, with each article accounting for a mean of $392,582 in direct costs [106]. 
Not surprisingly, there have been calls to institute more aggressive means of 
notification to the scientific community [107], yet the topic is rarely mentioned and 
different publishers differ in their retraction policies, which can make it not 
immediately obvious that a paper has been retracted [108]. Although retrieval of a 
publication in PubMed also retrieves the retraction statement, authors often rely on 
other authors’ citation to that work and so inadvertently enhance that articles 
legitimacy.  
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Biological relevance 
I would like to conclude with a brief mention of another reason for the low ratio of 
translation of research promise to real-life biomedical application. Much biomedical 
research is performed in a clinical and methodological vacuum [109] and research 
findings are frequently extrapolated from disease models that have little resemblance 
to the corresponding human condition [110]. Even though their unsuitability is 
occasionally recognised [111-118], there is a need to acknowledge more universally 
and transparently the known limitations in the clinical translation of non-human 
models in general to man [119]. No matter how transparent, well-designed, analysed 
and reported, if research results are obtained from inappropriate models they can 
never be translated into a valid human disease context.  
Conclusions 
Late in the day, editors of some of the major scientific journals have come to realise 
that they have been seriously negligent in their approach to overseeing the publication 
of reliable research results and have started to confront their responsibilities [120-
122]. A series of similarly worded editorials appeared in Nature Structural Biology 
[123], Nature Genetics [124], Nature Neuroscience [125], Nature Immunology [126], 
Nature Medicine [127], Nature Methods [128], Nature Cell Biology [129] and 
announced measures to “reduce irreproducibility”. These are a welcome, if long 
overdue acknowledgement of the journals’ acquiescence to such vast quantities of 
inadequate reporting of experimental detail in much of the peer-reviewed literature.  
However, the proof is in the pudding and an analysis of ten random papers published 
in late 2014 in Nature-titled journals [130-139] reveals the astonishing fact that there 
is actually less technical information provided than in the past (Table 1). Every single 
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publication uses a single, unvalidated reference gene for normalisation (all old 
favourites), all use the 2-∆∆Cq method with no attempt to calculate PCR efficiency and 
reporting of RNA quality control measures is non-existent. Yet for the ∆∆Cq 
calculation to be valid, the amplification efficiencies of target and reference must be 
approximately equal [130]; if not the PCR must be oprtimised [131]. What hope of 
ever changing anything if journal editors choose to ignore their own guidelines? 
In contrast, research published in Biomolecular Detection and Quantification (BDQ) 
will have to pass a careful double blind peer-review process that will examine the 
validity of its molecular study design, measurement, data analysis and reporting. Our 
aim is to establish a reputation for unbiased publishing of studies that adhere to best 
practice guidelines and promote excellence in molecular measurement and its data 
analysis. Subject areas are deliberately broad to allow BDQ to serve as a repository 
for sharing key findings across what may otherwise be disparate specialties. It is 
hoped that BDQ will attract a wide range of critical, thoughtful, well-designed and 
excellent publications to help provide the impetus towards a more transparent and 
meaningful scientific literature. 
Finally, the question “Modern biomedical research: an internally self-consistent 
universe with little contact with medical reality?” [110] should now be extended to 
include the addition “and based on an unacceptable level of technical proficiency”. It 
will be a long time before the many contradictions apparent in every area of the life 
sciences are addressed, never mind corrected [132]. But who is going to lead this 
effort, and how many vested interests will conspire to retain the status quo? 
Statement 
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The investigation on the measles virus/autism publication was carried out for the 
MMR vaccine litigation trial at the High Court of Justice in London and at the US 
Vaccine court. The author acted as an expert witness and was compensated by the 
solicitors acting for the principal defendants SmithKline Beecham Plc and Smith 
Kline & French Laboratories Ltd, Merck & Co Inc and Sanofi Pasteur MSD Ltd. The 
author also acted as an expert witness for the US Department of Justice and was paid. 
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 Legend 
Table 1. A search was carried out on the Nature web site (www.nature.com) for the 
term “reverse transcription real time PCR” and ten papers published in the second half 
of 2014 were selected at random. Materials and methods and supplementary 
information was examined for information on RT-qPCR protocols. 
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